Pharvaris reported Tuesday that its experimental oral therapy deucrictibant met the primary endpoint of a late‑stage clinical trial, delivering an 83% reduction in the average monthly rate of swelling attacks for patients with hereditary angioedema (HAE). The results, released by the company and covered by Reuters, signal a major step forward for individuals living with this rare genetic disorder.
Study design and patient population
The double‑blind, placebo‑controlled trial enrolled 85 adolescents and adults across 21 countries, representing all three recognized types of HAE. Participants received either deucrictibant or a matching placebo once daily for 24 weeks. Type 1 and Type 2 patients—those with low C1‑inhibitor levels or dysfunctional C1‑inhibitor—experienced an even larger reduction of 87% in attack frequency.
Rapid onset and safety profile
According to Pharvaris, the drug began showing protective effects within the first week of treatment, and the benefit persisted throughout the study period. Most adverse events were mild or moderate, and no serious side effects linked to the medication were reported. One participant in each arm discontinued the study due to a side effect, but no safety concerns were raised that would impede further development.
Implications for patients and families
Hereditary angioedema causes unpredictable swelling in the face, hands, feet, abdomen, and throat. Throat swelling can obstruct breathing and become life‑threatening, creating constant anxiety for patients and their families. An effective preventive therapy like deucrictibant could restore confidence in daily activities, reduce emergency room visits, and lessen the emotional and financial burden on households.
Next steps for regulatory approval
Pharvaris said it intends to seek U.S. Food and Drug Administration approval for the preventive treatment in the first half of 2027. The company also plans to present additional data on efficacy, safety, and patient‑reported outcomes at upcoming medical conferences, offering clinicians further insight into how the drug performs in real‑world settings.
Market reaction
Following the announcement, Pharvaris shares rose more than 25% in pre‑market trading, reflecting investor optimism about the commercial potential of a first‑in‑class oral preventive therapy for HAE.
Broader context
HAE affects an estimated 1 in 50,000 people worldwide, making it a rare but serious condition. Current treatment options include injectable C1‑inhibitor replacement and newer monoclonal antibodies, which can be costly and inconvenient. An effective oral option could broaden access, especially for patients in rural or underserved areas where frequent clinic visits are challenging.
While the trial results are encouraging, Pharvaris acknowledges that larger, longer‑term studies will be needed to confirm durability of response and to monitor rare adverse events. Nonetheless, the data provide a hopeful outlook for a community that has long awaited a convenient, reliable preventive solution.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
